Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (May 2023)
37 slides from Innate Pharma Sa Class A's investor presentation, May 2023
Slide 1: Company overview
Company overview MAY 2023
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Key Takeaways
Key Takeaways Create value for patients and shareholders Strategic Priorities Robust pipeline of Antibody engineering capabilities Advancing lacutamab Maximizing ANKET® platform Continuing to explore ADC Early R&D focus to drive value through later stage Track record of strategic partnerships AstraZ
Slide 4: Upcoming catalysts
Upcoming catalysts Delivering across our strategic objectives • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201(CD39) MATISSE | Phase 2 readout (AZ) • IPH6101 / SAR’579 ANKET ® (CD123) | Phase 1 (Sanofi) • IPH6501 ANKET® (CD20) | IND Filing • IP
Slide 5: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Upcoming Milestone Sezary syndrome TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) Final data H2 2023 Mycosis Fungoides TELLOMAK Final data H2 2023 Lacutamab KIR3DL2 PTCL (combo with
Slide 6: Innate Pharma snapshot
Innate Pharma snapshot Global, clinical-stage oncology-focused biotech company. Scientific excellence in the field of innate immunity with expertise in Natural Killer (NK) cell biology and antibody engineering. Focused pipeline of antibodies, including several potentially first-in-class clinical and
Slide 7: Scientific innovation drives our strategy
Scientific innovation drives our strategy Our ambition – leverage our scientific know-how in innate Advance our Build a sustainable Drive near-term value immunity and antibody engineering to innovative business through with lacutamab develop cancer drugs that improve the Drive near-term value pipeli
Slide 8: Innate's approach: harnessing innate immunity in cancer
Priming and activation (APCs and T cells) Innate’s approach: harnessing innate immunity in cancer Cancer antigen presentation (DCs) Choosing the right targets to leverage the body’s immune response Lymph node 01 Trafficking of T cells to tumors Amplification of the innate immune response Engage NK c
Slide 9: Building a robust pipeline on strong basics
Building a robust pipeline on strong basics Validated Strong track record Science of collaborations Validated in high-impact Strong track with industry Robust Science publications recordand ofacademia pipeline collaborations 5 drug candidates in clinical stage Including 2 proprietary and 3 in partne
Slide 10: Drive near-term value with lacutamab
Drive near-term value with lacutamab 10
Slide 11: Lacutamab: lead proprietary asset
LACUTAMAB Lacutamab: lead proprietary asset First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL). Compelling Phase 1 data in Sezary syndrome (SS), published in Lancet Oncology. EMA PRIME and FDA
Slide 12: Compelling Phase 1 Results Sezary Syndrome Subgroup
LACUTAMAB Compelling Phase 1 Results Sezary Syndrome Subgroup (n=35) FDA Fast Track Designation granted based on these results. Total 44 patients with CTCL ≥ 2 lines of therapy • 25 (incl. 20 SS) in dose escalation (intra-patient dose escalation was allowed). • 19 (incl. 15 SS) in cohort expansion.
Slide 13: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 treatment. Cutaneous T cell lymphoma Sézary syndrome Sezary ~ 80 - 200 patients Fast to market >90% KIR3DL2 expression approach Niche indication with high unmet need Mycosis fungoid
Slide 14: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 treatment. Cutaneous T cell lymphoma TELLOMAK Sézary syndrome Sezary Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 >90% KIR3DL2 expression Cohort 1 (N~60) 3 cohorts (N~100)
Slide 15: Lacutamab | Preliminary efficacy results in CTCL support further development
LACUTAMAB Lacutamab | Preliminary efficacy results in CTCL support further development Final data from TELLOMAK Phase 2 trial in H2 2023 Sézary syndrome Best global response Best skin response Best blood response 21.6% 35.1% 37.8% Cohort 1 (N~60) Minimum of 2 prior therapies, including mogamulizumab
Slide 16: Initiating data-driven strategy in PTCL
Initiating data-driven strategy in PTCL Now Next steps RELAPSED SETTING FRONTLINE Highest unmet medical need Driven by data in the relapsed setting to advance into earlier lines Monotherapy (Phase 1b study in H2 2021) Combination with GemOx Combination with CHOP (LYSA-sponsored Phase 2 KILT study in
Slide 17: Advance our innovative R&D pipeline
Advance our innovative R&D pipeline 17
Slide 18: NK Cells Offer Unique Cancer-Fighting Abilities
ANKET® NK Cells Offer Unique Cancer-Fighting Abilities NK Specificity NK cells in NK cells are not expected to produce a cytokine storm periphery NKp46 is the most specific activating receptor of NK cells NKp46 NKp46 Expression Stability NK cells in Unlike many other activating receptors, NKp46 is s
Slide 19: Proprietary NK cell engager platform
ANKET® Proprietary NK cell engager platform Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46. Provides proliferation and activation signals targeted to NK cells. Demonstrates better anti-tumor efficacy than approved benchmar
Slide 20: ANKET NK cell engager molecules control tumor proliferation
ANKET® ANKET® NK cell engager molecules have the potential to strongly control tumor proliferation via the proliferation and activation of NK cells Growing clinical pipeline Innate Pharma differentiated MoA IPH6101 / SAR’579 (CD123) Phase 1 Nature Biotechnology January 2023 IPH6401 / SAR’514 (BCMA)
Slide 21: IPH6101/SAR'579 Oral presentation at ASCO 2023
ANKET® IPH6101/SAR’579 Oral presentation at ASCO 2023 IPH6101/SAR’579 is the first NKp46/CD16-based NK cell engager using Innate’s proprietary multispecific antibody format ANKET® Preclinical rationale Abstract selected for an oral presentation at the 2023 ASCO Annual Congress IPH6101 induced AML ca
Slide 22: Optimal Efficacy Requires All Arms in Tetra-specific ANKET
ANKET® Optimal Efficacy Requires All Arms in Tetra-specific ANKET® Demonstrate Superiority in Preclinical Model of Tumors Solid tumor models Disseminated tumor models Vehicule Obinutuzumab* IPH6501 IND filing in 2023 – Oral presentation at EHA in June 2023 TAg: Tumor antigen 22
Slide 23: Different Receptors have Different Effects on NK cells
ANKET® Different Receptors have Different Effects on NK cells NKG2D NKp46 CD16 IL-2Rb DAP10 CD3ζ, FcRγ # IL-2Rg NK cell activation + NK cell activation +++ Proliferation +++ Cytotoxicity Cytotoxicity Cytokines and chemokines Adapted from Lanier, Nature Immunol 2008; Vivier et al., Science, 2004 23
Slide 24: Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73)
ADENOSINE Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 Clinical trials underway (anti-CD73) IPH5201 (anti-CD39) Phase 1 completed Phase 2 MATISSE ongoing Advanced solid tumors NeoAdj/Adj Non small cell lung cancer Combination IPH5201 + durvalumab Combination IPH5201+durvalumab+/- chemotherapy
Slide 25: IPH5201: Phase 2 clinical trial MATISSE initiated
IPH5201 IPH5201: Phase 2 clinical trial MATISSE initiated Phase 1 in advanced solid tumors Preclinical data + Phase 2 trial MATISSE ongoing completed (sponsor: AstraZeneca) Best change in tumor size from baseline Non small cell lung cancer (NSCLC) IPH5201 monotherapy IPH5201 + durvalumab Neoadjuvant
Slide 26: IPH5301: Phase 1 clinical trial ISS CHANCES ongoing
IPH5301 IPH5301: Phase 1 clinical trial ISS CHANCES ongoing Preclinical data Phase 1 CHANCES ongoing (sponsor: IPC) IPH5301 epitope translates into superior blocking capacity on both membrane and soluble CD73 and superior T cell activation Advanced Solid Tumors PART 01 IPH5301 Dose escalation PART 0
Slide 27: Build a sustainable business through partnerships
Build a sustainable business through partnerships 27
Slide 28: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Late-stage clinical trial highlights Monalizumab blocks the NKG2A receptor AstraZeneca initiated Phase 3 trial, PACIFIC-9 on both NK cells and cytotoxic CD8+ T with monalizumab + durvalumab in patients with
Slide 29: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials Covering early stages of lung cancer Stages of the disease Upcoming presentation NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major pathological Patients with Stage II to IIIB NSCLC NSCLC response Stages I - III vs. 11% durva
Slide 30: Strategic partnership with AstraZeneca
MONALIZUMAB Strategic partnership with AstraZeneca Monalizumab Milestone payment of $50 million received from AstraZeneca for the first patient treated in the Phase 3 trial, PACIFIC -9. Amounts received Total amount of the agreement: 1.275 billion US$ Total milestones Milestone Initial payments 250
Slide 31: Strategic partnership with AstraZeneca: IPH5201
IPH5201 Strategic partnership with AstraZeneca IPH5201 Milestone payments $60m Potential total amount of the Already received agreement Including $5 million in milestone payment for the launch of the MATISSE Phase 2 trial. $885 million Royalties on sales Outside Europe AstraZeneca will record all sa
Slide 32: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Three molecules licensed to Sanofi plus two undisclosed targets under options IPH6101/SAR’579 IPH6401/SAR’514 IPH62 OPTION Ongoing CD123 BCMA B7-H3 2 undisclosed programs Phase 1 in AML Progression towards IND Research targets Payments received
Slide 33: Partnership between Takeda and Innate
Partnership between Takeda and Innate Exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) ADC using a panel of selected antibodies developed by Innate Ongoing Undisclosed target programs Preclinical stage – with a primary focus in Celiac disease Paymen
Slide 34: Key takeaways
BS innate pharma With our strong foundations and clear strategy, we are pursuing our development with determination to create value for patients and all our stakeholders
Slide 35: Upcoming catalysts
Upcoming catalysts Delivering across our strategic objectives • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201(CD39) MATISSE | Phase 2 readout (AZ) • IPH6101 / SAR’579 ANKET ® (CD123) | Phase 1 (Sanofi) • IPH6501 ANKET® (CD20) | IND Filing • IP
Slide 36: Key Takeaways
Key Takeaways Create value for patients and shareholders Strategic Priorities Robust pipeline of Antibody engineering capabilities Advancing lacutamab Maximizing ANKET® platform Continuing to explore ADC Early R&D focus to drive value through later stage Track record of strategic partnerships AstraZ
Slide 37: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA